↓ Skip to main content

A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol

Overview of attention for article published in Frontiers in Pharmacology, February 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
3 news outlets
blogs
1 blog
twitter
18 X users
facebook
3 Facebook pages
reddit
1 Redditor

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
165 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol
Published in
Frontiers in Pharmacology, February 2017
DOI 10.3389/fphar.2017.00081
Pubmed ID
Authors

Salahaden R. Sultan, Sophie A. Millar, Timothy J. England, Saoirse E. O'Sullivan

Abstract

Despite cannabidiol (CBD) having numerous cardiovascular effects in vitro, its haemodynamic effects in vivo are unclear. Nonetheless, the clinical use of CBD (Epidiolex) is becoming more widespread. The aim of this systematic review was to establish whether CBD is associated with changes in haemodynamics in vivo. Twenty-five studies that assessed the haemodynamic effects of CBD (from PubMed, Medline and EMBASE) were systematically reviewed and meta-analyzed. Data on blood pressure (BP), heart rate (HR), and blood flow (BF) were extracted and analyzed using random effects models. Twenty-two publications assessed BP and HR among 6 species (BP n = 344 and HR n = 395), and 5 publications assessed BF in 3 species (n = 56) after acute dosing of CBD. Chronic dosing was assessed in 4 publications in 3 species (total subjects BP, n = 6; HR, n = 27; BF, n = 3). Acute CBD dosing had no effect on BP or HR under control conditions. Similarly, chronic dosing with CBD had no effect on HR. In models of stress, acute CBD administration significantly reduced the increase in BP and HR induced by stress (BP, mean difference (MD) -3.54, 95% CI -5.19, -1.9, p < 0.0001; HR, MD -16.23, 95% CI -26.44, -6.02, p = 0.002). In mouse models of stroke, CBD significantly increased cerebral blood flow (CBF, standardized mean difference (SMD) 1.62, 95% CI 0.41, 2.83, p = 0.009). Heterogeneity among the studies was present, there was no publication bias except in HR of control and stressful conditions after acute CBD dosing, and median study quality was 5 out of 9 (ranging from 1 to 8). From the limited data available, we conclude that acute and chronic administration of CBD had no effect on BP or HR under control conditions, but reduces BP and HR in stressful conditions, and increases cerebral blood flow (CBF) in mouse models of stroke. Further studies are required to fully understand the potential haemodynamic effects of CBD in humans under normal and pathological conditions.

X Demographics

X Demographics

The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 165 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 28 17%
Student > Master 20 12%
Other 15 9%
Student > Bachelor 15 9%
Student > Ph. D. Student 14 8%
Other 29 18%
Unknown 44 27%
Readers by discipline Count As %
Medicine and Dentistry 29 18%
Pharmacology, Toxicology and Pharmaceutical Science 19 12%
Biochemistry, Genetics and Molecular Biology 11 7%
Agricultural and Biological Sciences 10 6%
Neuroscience 7 4%
Other 38 23%
Unknown 51 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 43. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2023.
All research outputs
#971,056
of 25,516,314 outputs
Outputs from Frontiers in Pharmacology
#361
of 19,877 outputs
Outputs of similar age
#19,915
of 325,228 outputs
Outputs of similar age from Frontiers in Pharmacology
#8
of 200 outputs
Altmetric has tracked 25,516,314 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,877 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,228 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 200 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.